Whole-genome sequencing of patients with rare diseases in a national health system by Turro, Ernest et al.
                          Turro, E., Mumford, A. D., Saleem, M. A., & al., E. (2020). Whole-
genome sequencing of patients with rare diseases in a national health
system. Nature, 583, 96-102. https://doi.org/10.1038/s41586-020-
2434-2
Peer reviewed version
Link to published version (if available):
10.1038/s41586-020-2434-2
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Nature Research at https://www.nature.com/articles/s41586-020-2434-2 . Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Whole-genome sequencing of rare disease patients in 
a national healthcare system 
 
Willem H Ouwehand, on behalf of the NIHR BioResource and the 100,000 Genomes Project* 
*A full list of authors and their affiliations appears at the end of the manuscript and a list of 
collaborators and their affiliations appears at the end of the Supplementary Information. 
 
 
Most patients with rare diseases do not receive a molecular diagnosis and the aetiological 
variants and mediating genes for more than half such disorders remain to be discovered. We 
implemented whole-genome sequencing (WGS) in a national healthcare system to streamline 
diagnosis and to discover unknown aetiological variants, in the coding and non-coding regions 
of the genome. In a pilot study for the 100,000 Genomes Project, we generated WGS data for 
13,037 participants, of whom 9,802 had a rare disease, and provided a genetic diagnosis to 
1,138 of the 7,065 patients with detailed phenotypic data. We identified 95 Mendelian 
associations between genes and rare diseases, of which 11 have been discovered since 2015 
and at least 79 are confirmed aetiological. Using WGS of UK Biobank1, we showed that rare 
alleles can explain the presence of some individuals in the tails of a quantitative red blood cell 
(RBC) trait. Finally, we reported 4 novel non-coding variants which cause disease through the 
disruption of transcription of ARPC1B, GATA1, LRBA and MPL. Our study demonstrates a 
synergy by using WGS for diagnosis and aetiological discovery in routine healthcare. 
 
 
Rare diseases affect approximately 1 in 20 people, but only a minority of patients receive a 
genetic diagnosis2. Approximately 10,000 rare diseases are known, but fewer than half have a 
resolved genetic aetiology3. Even when the aetiology is known, the prospects for diagnosis are 
severely diminished by a fragmentary approach to phenotyping and the restriction of genetic 
testing to a disease-specific panel of genes. On average, a molecular cause is determined after 
three misdiagnoses and 16 physician visits over a “diagnostic odyssey” lasting more than two 
years4. However, recent developments in WGS technology mean it is now possible to perform 
comprehensive genetic testing systematically in an integrated national healthcare system. The 
large-scale implementation of WGS for diagnosis will also enable the discovery of new genetic 
aetiologies, through the identification of novel causal mutations in the coding and non-coding 
parts of the genome. 
 
In a pilot study for the 100,000 Genomes Project supported by the National Institute for Health 
Research (NIHR), we have performed WGS of 13,037 individuals enrolled at 57 National Health 
Service (NHS) hospitals in the United Kingdom and 26 hospitals in other countries (Fig. 1a, 
Extended Data Fig. 1a, Supplementary Table 1) in three batches, to clinical standard (Fig. 1b). 
The participants were distributed approximately equally between the sexes (Supplementary 
Table 1) and their distribution across ethnic groups closely matched that reported in the UK 
census (Fig. 1c; https://www.ons.gov.uk/census/2011census). In total, 9,802 participants (75%) 
were affected with a rare disease or had an extreme measurement of a quantitative trait, of 
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which 9,024 were probands and 778 were affected relatives. Each participant was assigned to 
one of 18 domains (Table 1): 7,388 individuals to one of 15 rare disease groups, 50 individuals 
to a control group, 4,835 individuals to a Genomics England Limited (GEL) group and 764 
individuals to a group of UK Biobank participants with extreme red blood cell indices 
(Supplementary Information). The rare disease domains covered pathologies of a wide range of 
organ systems and each had pre-specified inclusion and exclusion criteria (Supplementary 
Information, Supplementary Table 1, Extended Data Fig. 1b). The variation in sample size 
across domains was primarily due to differences in recruitment rate, which limited the efficiency 
of the experimental design. We subsequently collected detailed phenotypic information, through 
web-based data capture applications, in the form of Human Phenotype Ontology (HPO) terms 
for 13 of the rare disease domains (Fig. 2a,b, Extended Data Fig. 1c). Patients with diverse 
diagnoses were enrolled to the GEL domain, together with healthy family members, but only the 
affection status of these participants were available for this study. In addition, HPO-coded 
phenotypes were not collected for Leber Hereditary Optic Neuropathy (LHON) and Ehler-Danlos 
and Ehler-Danlos-like Syndromes (EDS) patients. In total, 19,605 HPO terms were selected to 
describe patient phenotypes. Quantitative data were transcribed to HPO terms using domain-
specific rules, while free text was transcribed manually. 
 
Domain name Acronym Participants Rare diseases HPO/Clinical 
reporting 
Bleeding, Thrombotic and Platelet Disorders BPD 1169 Y Y 
Technical Controls CNTRL 50 N N 
Cerebral Small Vessel Disease CSVD 246 Y Y 
Ehler-Danlos and Ehler-Danlos-like Syndromes EDS 17 Y Y 
100,000 Genomes Project–Rare Diseases Pilot GEL 4835 Y N 
Hypertrophic Cardiomyopathy HCM 252 Y Y 
Intrahepatic Cholestasis of Pregnancy ICP 268 Y Y 
Inherited Retinal Disorders IRD 725 Y Y 
Leber Hereditary Optic Neuropathy LHON 71 Y Y 
Multiple Primary Malignant Tumours MPMT 588 Y Y 
Neurological and Developmental Disorders NDD 660 Y Y 
Neuropathic Pain Disorders NPD 193 Y Y 
Pulmonary Arterial Hypertension PAH 1148 Y Y 
Primary Immune Disorders PID 1359 Y Y 
Primary Membranoproliferative Glomerulonephritis PMG 184 Y Y 
Stem cell and Myeloid Disorders SMD 257 Y Y 
Steroid Resistant Nephrotic Syndrome SRNS 251 Y Y 
UK Biobank – Extreme Red Cell Traits UKB 764 N N 
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Table 1. Study domain names, acronyms, numbers of participants, whether the domain 
included cases with a rare disease and whether domain participants were assigned HPO 
terms for diagnostic reporting. 
 
Following bioinformatic quality control (QC) and data analysis (Extended Data Fig. 2–4), we 
identified 172,005,610 short variants, of which 157,411,228 (91.5%) were single nucleotide 
variants (SNVs) and 14,594,382 (8.5%) were indels up to 50bp long (Extended Data Fig. 5). 
48.6% and 40.8% of the SNVs and indels, respectively, were absent from all major variant 
databases (Fig. 1e). 54.8% of the variants were observed in only one member of the maximal 
set of 10,259 unrelated participants, of which 82.6% were novel. Only 9.08% of novel variants 
were observed in more than one member of the unrelated set, typically in sets of individuals with 
recent common ancestry (Fig. 1f). SNVs and indels common in our dataset were well 
represented in genetic databases but, in accordance with theory, the vast majority of the 
variants we observed were very rare and most were uncatalogued. We called 24,436 distinct 
large deletions (>50bp) by synthesising inferences from two algorithms across individuals. We 
also called more complicated types of structural variant, such as inversions, but they were 
called unreliably and could not be confidently aggregated across individuals (Supplementary 
Information). We used the WGS data to determine that only 13 (0.1%) individuals had non-
standard sex chromosomal karyotypes (Extended Data Fig. 3e–g). Using the high quality variant 
calls, we inferred a wide range of bioinformatically estimated family sizes, in keeping with 
differences in enrolment strategies (Supplementary Information), of which most comprised 
singletons (Fig. 1d). 
 
We issued clinical reports for 1,103 distinct causal variants (731 SNVs, 264 indels, 102 large 
deletions, 6 other structural variants) affecting 303 genes (Extended Data Fig. 5). 266 of the 995 
SNVs and indels (26.7%) were absent from the Human Gene Mutation Database (HGMD) and 
from the set of variants in ClinVar having a pathogenic or likely pathogenic interpretation and no 
benign interpretations. We identified strong evidence (posterior probability (PP) > 0.75) for 99 
genetic associations between rare variants and groupings of patients with similar phenotypes 
using the Bayesian genetic association method, BeviMed5. Of these 99 associations, 62 are 
consistent with firmly established evidence and a further 11 have been reported in the literature 
since 2015, either by us or by other researchers. We showed that genetic associations with the 
extremes of a quantitative trait can identify genes in which mutations cause Mendelian 
pathologies. Finally, we used a novel method, RedPop, to call cell-type specific regulatory 
elements (REs) from open chromatin and histone modification data. We combined these calls 
with cell-type specific transcription factor binding information to identify four pathogenic rare 
non-coding variants that cause disease by disrupting the proper regulation of gene expression. 
 
Summary of clinical findings 
For each of the 15 rare disease domains, we established a list of diagnostic-grade genes 
(DGGs) and lists of their corresponding transcripts on the basis of the scientific literature 
(Supplementary Information). The number of DGGs for each domain ranged from two for 
Intrahepatic Cholestasis of Pregnancy (ICP) to 1,423 for Neurological and Developmental 
Disorders (NDD). The DGG lists were not mutually exclusive because some genes harbour 
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mutations that cause pathologies compatible with the enrolment criteria of multiple domains 
(Fig. 2c). Twelve multidisciplinary teams (MDTs) with domain-specific expertise examined the 
rare variants observed in DGGs in the context of the HPO phenotypes of the carriers. They 
categorised a subset of the variants as pathogenic or likely pathogenic following standard 
guidelines6 and assessed their allelic contribution to disease as full or partial. A variant's 
contribution was considered to be at least partial if, given all other known variants in the case, it 
was considered to have a disease determining consequence. A conclusive molecular diagnosis 
was returned for 1,138 of the 7,065 (16.1%) patient records reviewed and those diagnoses 
featured 1,103 distinct causal variants (Supplementary Table 2). One quarter of the reports 
featured variants in BMPR2, ABCA4 and USH2A and a further quarter featured variants in a 
group of 18 DGGs. The remaining half of the clinical reports concerned variants spread across 
306 DGGs, which often featured in a single report (Fig. 2d, Extended Data Fig. 6). The 
diagnostic yield by domain ranged from no patients out of 184 (0%) for Primary 
Membranoproliferative Glomerulonephritis (PMG) to 391 patients out of 725 (53.9%) for 
Inherited Retinal Disease (IRD). The variability of diagnostic yield can be attributed to 
heterogeneity in: phenotypic and genetic pre-screening before enrolment, the genetic 
architecture of diseases and prior knowledge of genetic aetiologies.  
 
Clinical reporting was enhanced by the use of PCR-free WGS with a mean autosomal depth 
>35X instead of whole-exome sequencing (WES). For example, a causal SNV encoding a start 
loss of HPS6 in a case with Hermansky-Pudlak syndrome was identified by WGS but not 
identified by WES prior to the study. We compared the coverage obtained from  the WGS 
samples to coverage obtained from research WES of UK Biobank samples 
(https://www.biorxiv.org/content/10.1101/572347v1), INTERVAL samples7 and samples from the 
Columbia University exome sequencing study for chronic kidney disease8 (Supplementary 
Information). Although less costly to generate per sample, all WES datasets exhibited much 
greater variation in coverage within and between genomic sites harbouring known pathogenic 
SNVs or indels than WGS (Extended Data Fig. 7). Of the 938 distinct autosomal aetiological 
SNVs and indels reported in this study, 25–99 (2.67%–10.5%) had insufficient coverage in WES 
for reliable genotyping, depending on dataset (Extended Data Fig. 7). Moreover, deletions 
spanning only a few short exons or part of a single exon are not reliably called by WES9,10. Of 
the 102 distinct large deletions that we reported (length range 203bp–16.80Mb, mean 
786.33Kb, median 15.91Kb), 22 (21.6%) overlapped only one exon. 
 
Our recent genetic discoveries have informed treatment decisions: 27 patients with early-onset 
dystonia due to variants in KMT2B can be treated by deep brain stimulation11; cases with 
DIAPH1-related macrothrombocytopenia and deafness12 can have their platelet count restored 
to a safe level in a preoperative setting with Eltrombopag13; and a case of severe 
thrombocytopenia accompanied by myelofibrosis and bleeding caused by a gain-of-function 
variant in SRC14 was cured by an allogeneic haematopoietic stem cell transplant. In addition, 
our diagnoses have helped stratify patient care: patients with Primary Immune Disorders (PID) 
due to variants in NFKB1, which we have shown are the commonest monogenic cause of 
combined variable immunodeficiency (CVID)15, have unexplained splenomegaly and an 
increased risk of cancer; 27 cases from the Bleeding, Thrombotic and Platelet Disorders (BPD) 
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domain with isolated thrombocytopenia caused by variants in ANKRD26, ETV6 or RUNX1 have 
an increased risk of malignancy16,17,18 compared to 19 cases with benign thrombocytopenia due 
to variants in ACTN1, CYCS or TUBB119. Furthermore, our discoveries have improved the 
accuracy of prognosis, which is worse for patients with Pulmonary Arterial Hypertension (PAH) if 
the cause is mutations in BMPR220 or EIF2AK421, while the impact of mutations in ATP13A3, 
AQP1, GDF2 and SOX17, genes which we have recently reported as aetiological22, remains to 
be determined. 
 
Quantitative intermediate phenotypes can contain information that is useful for understanding 
genetic aetiology in difficult to diagnose patients. We examined WGS read alignments for 
patients with complete absence of a protein encoded by a DGG but carrying an explanatory 
variant call on only one haplotype. Two patients with a severe unexplained bleeding disorder 
due to the absence of αIIbβ3 integrin on their platelet membranes carried two different complex 
variants in intron 9 of ITGB3: a tandem repeat and an SVA retrotransposon which was not 
called by either of the two structural variant callers we employed, but was discernible due to an 
excess of improperly mapped reads and confirmed by long-read nanopore sequencing 
(Extended Data Fig. 8a–e). The third patient had an absence of RhD and RhCE proteins on the 
membrane of her red cells leading to severe haemolytic anemia. This was due to a large 
tandem repeat in RHAG, which encodes the Rh-associated glycoprotein (Extended Data Fig. 
8f). 
  
Discovery of rare variants associated with rare diseases 
Several cases with similar aetiologies are typically needed to make a novel discovery in rare 
disease genetics. Cases can be aggregated across siloed studies, using services such as 
Matchmaker Exchange (MME)23. We used MME to identify novel aetiologies for SLC18A224 and 
WASF125 (Supplementary Information). However, in the context of a study of a unified 
healthcare system, it is possible to make discoveries by statistical analyses of large patient 
collections. 
 
We applied the statistical method BeviMed5 to identify genetic associations between gene loci 
and rare diseases under various modes of Mendelian inheritance (Supplementary Information). 
We defined a set of phenotypic tags for each domain to determine a set of case/control 
groupings for BeviMed. Groups of cases were assigned the same tag if their phenotypes were a 
priori judged compatible with a shared genetic aetiology of disease (Supplementary Table 3). 
The number of unrelated cases in each tag group ranged from three for Roifman syndrome to 
1,101 for PAH. For each gene-tag pair, we compared the genotypes at rare variant sites 
between unrelated individuals with the tag (cases) and unrelated individuals without the tag 
(controls). We considered a PP of association >  0.75 to be strong evidence supporting a 
genetic aetiology. Additionally, for each analysis BeviMed inferred a conditional PP over the 
mode of inheritance, a conditional PP over the molecular consequence class of variants 
mediating disease risk (e.g. 5’ UTR variants or predicted loss-of-function variants) and 
conditional PPs of pathogenicity for each specific variant. These quantities were used to 
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compare established to inferred modes of inheritance and to estimate the number of cases 
attributable to variants in each gene5. 
 
We inferred strong evidence for an association between each of 95 genes, spanning nine 
domains, and one of 29 phenotypic tags. These genes included 68 established DGGs, 11 
DGGs discovered since 201515,26,27,22,28,29,30,31,22,32,33 and 16 candidates requiring further 
investigation (Fig. 3; Supplementary Table 3). Thus, 79 of 95 genetic associations are 
confirmed, which sets a lower bound on the observed positive predictive value (PPV) of 83%, 
which is broadly in line with an ancestry-controlled statistical estimate of the study-wide PPV of 
79% (Supplementary Information). We estimated that 611.3 cases can be explained by rare 
variants in the 79 genes with a confirmed association, 115.6 of which can be explained by the 
association between variants in BMPR2 and PAH. 51 of the 95 genetic associations relied only 
on evidence from alleles carried by single cases, showing the power of joint statistical modelling 
of rare variants. Only three of the unconfirmed associations relied on evidence from alleles 
carried by more than one case, demonstrating the robustness of the results to cryptic 
relatedness. For one gene (GP1BB), the mode of inheritance inferred by BeviMed differed from 
that established in the literature, challenging long-held assumptions34. These results and other 
findings from this project22,35,36,37,25,38,15,39,40,10,19,41,42,25,43,11,44,12,45 show that a unified analysis of 
standardised homogeneously collected genetic and phenotypic data from large cohorts of 
different rare disease domains is a powerful approach for genetic discovery. 
 
Polygenic and rare variant associations with the extremes of a quantitative trait in 
UK Biobank 
Several rare diseases (e.g. familial hypercholesterolaemia, CVID, thrombocytopenia, von 
Willebrand disease) are diagnosed and clinically characterised by reference to a quantitative 
trait that acts as a causal intermediate (or close proxy) for pathology and symptoms. Mutation-
selection equilibrium ensures strong negative selection in the extreme tails of heritable 
quantitative traits, so individuals in the tails should have lower fecundity, perhaps due to greater 
risk of disease. We sought to identify genes likely to carry mutations causing RBC pathologies 
by computing a univariate quantitative summary of baseline RBC full blood count (FBC) traits in 
the UK Biobank participants of European ancestry. We aimed to develop a red cell phenotype 
capturing as much rare-variant heritability as possible. To achieve this, we used the joint 
distribution of estimated effect sizes from published GWAS associations between variants with 
MAF < 1% and four mature RBC FBC traits as a model for the effect of causal rare alleles we 
hoped to identify by WGS46 (Fig 4a). We successfully sequenced 764 participants, 383 of which 
were extreme for the left tail of the phenotype, corresponding to a low RBC count (RBC#) and a 
high mean cell volume (MCV), and 381 of which were extreme for the right tail of the phenotype, 
corresponding to a high RBC# and a low MCV (Fig. 4b,c).  
 
The distribution of a polygenic predictor of the quantitative phenotype, derived from genetic 
variants known to be associated with RBC# and MCV exhibits left and right shifts from the 
population distribution in the respectively named tails (Fig. 4d). However, these shifts are not as 
strong as those predicted by Gaussian variance components modelling, a discrepancy which 
could be explained partly by rare alleles generating excess density in the tails (kurtosis 6.9). A 
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WGS GWAS of an ordinal outcome (left tail, unselected, right tail) did not yield novel 
associations. Consequently, we treated each of the tail groups as a set of cases in a BeviMed 
analysis, identifying 12 genes with PP evidence for an association stronger than 0.4, a liberal  
threshold (Fig. 4e). HBB and TFRC can be considered positive controls, as they are known to 
carry mutations causing Mendelian microcytic anaemias. Other genes, including CUX1 and 
ALG1 are biologically plausible candidates. These results (Supplementary Table 3) indicate that 
the analysis of quantitative extremes in apparently healthy population samples may identify 
medically relevant loci unidentified by GWAS for quantitative traits46,47. 
 
Aetiological variants in regulatory elements 
Recent statistical modelling suggests that only a small proportion of the burden of heritable 
neurodevelopmental disorders can be attributed to de novo pathogenic SNVs in non-coding 
elements48. Nevertheless, rare variants in REs are known to cause disease by disrupting 
transcription or translation49,50,51. We searched for aetiological variants in the REs of 246 DGGs 
implicated in recessive haematopoiesis-related disorders. Firstly, we defined a set of active REs 
we named a ‘regulome’ for each of six blood progenitor and mature blood cell types. We 
achieved this by merging transcription factor binding sites identified by ChIP-seq with genomic 
regions called by RedPop, a new detection method exploiting the anti-covariance of ATAC-seq 
and H3K27ac ChIP-seq coverage in REs (Supplementary Information). We linked the REs to 
genes on the basis of genomic proximity and promoter capture Hi-C data52. Secondly, we 
assigned each regulome to one or more of the BPD, PID and Stem Cell and Myeloid Disorders 
(SMD) domains, depending on the relevance of the corresponding cell types to these domains 
(Supplementary Table 3). Finally, we searched for cases carrying a rare homozygous or 
hemizygous deletion of an RE active in a cell type assigned to the domain of the case and 
which was linked to a DGG of that domain. We also searched for heterozygous deletions 
meeting these criteria that were in compound heterozygosity with a rare coding variant in a 
DGG linked to the deleted element (Fig. 5a). These approaches explained three cases: a PID 
patient carrying a deletion overlapping the 5' UTR region of ARPC1B in compound 
heterozygosity with a frameshift variant in the same gene (Thaventhiran et al, under review), a 
nine year old boy with autism spectrum disorder and thrombocytopenia carrying a hemizygous 
deletion of a GATA1 enhancer on the X chromosome, and a male with several autoimmune-
mediated cytopenias carrying a homozygous deletion of intronic CTCF binding sites53 of LRBA. 
 
The X-linked deletion in the boy with autism (Extended Data Fig. 9a–b) removed an element 
regulating GATA1 as well as exons 1-4 of HDAC6. He had a persistently low platelet count 
(52x109/l), a mean platelet volume in the 99.9th percentile of the distribution for UK Biobank 
males (Fig. 5b)54 and normal RBC parameters except for mild dyserythropoiesis. Electron 
microscopic imaging of his platelets showed reduced α-granule content (Extended Data Fig. 9c–
e). Culture of his stem cells recapitulated ineffective formation of platelets by megakaryocytes 
(Extended Data Fig. 9f–k). Macrothrombocytopenia, reduced α-granule content, ineffective 
platelet formation and dyserythropoiesis are all characteristic of patients with pathogenic coding 
mutations of GATA155,56. His platelets contained reduced GATA1 (Fig. 5g), consistent with 
reduced transcription due to deletion of the GATA1 enhancer57. HDAC6 is the major 
deacetylase for removing the acetyl group from Lys40 of α-tubulin, which is located in 
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polymerized microtubules58. The absence of HDAC6 in the child was accompanied by extremely 
high expression levels of acetylated α-tubulin in his platelets (Fig. 5e), concordant with 
observations of Hdac6 knockout mice59. This aberrant acetylation is associated with bleeding59 
and altered emotional behaviour60 in mice. Thus, the reduced expression of GATA1 and the 
absence of HDAC6 jointly cause a new syndrome of macrothrombocytopenia accompanied by 
neurodevelopmental problems.  
 
The patient with a homozygous deletion of a CTCF binding site in the first intron of LRBA 
presented with a pancytopenia, characterised mostly by neutropenia and anaemia, and 
complicated by periods of thrombocytopenia. These cytopenias were mediated by 
autoantibodies due to a loss of tolerance for multiple autoantigens, which is characteristic of 
patients with reduced LRBA function61. 
 
We adapted our approach to solving cases caused by non-coding deletions to search for non-
coding SNVs with a CADD62 score > 20, in the presence of a high-impact coding variant in 
compound heterozygosity in the assigned DGG. This approach identified two potentially 
aetiological SNVs in elements assigned to AP3B1 and MPL, and we studied the 10 year old 
male patient carrying the latter mutation in more detail. MPL encodes the receptor for the 
megakaryocyte growth factor thrombopoietin63. Loss of MPL causes chronic amegakaryocytic 
thrombocytopenia in humans64 and Mpl knockout mice have severe thrombocytopenia65,66. The 
SNV (chr1:43803414 G>A) was in an RE detected by RedPop, the activity of which is specific to 
megakaryocytes in blood cell physiology (Extended Data Fig. 10), had a CADD score of 21.8, 
was absent from gnomAD, and was in compound heterozygosity with a deletion of exon 10 of 
MPL, which was inherited from the patient’s mother (Extended data, Fig. 10a,b,c). A luciferase 
reporter assay showed approximately 50% reduced promoter activity for the A allele compared 
to the reference allele (Extended Data Fig. 10d). As a result, platelet MPL levels were 
significantly reduced in the patient compared to controls (Extended Data Fig. 10e). In contrast to 
MPL-null patients67, who are extremely thrombocytopenic because their bone marrow is almost 
devoid of megakaryocytes and eventually suffer haematopoietic stem cell exhaustion, this boy 
had platelet counts which stabilised around 45x109/l and a marrow that was only moderately 
depleted of megakaryocytes. As the regulatory SNV does not abolish MPL transcription 
completely (Extended Fig. 10c), the boy has a milder clinical phenotype than MPL-null cases. 
 
Discussion 
Before now there has been limited integration between clinical genetic testing services and 
aetiological studies of rare diseases on a national scale. We have shown that WGS in a 
universal national healthcare system can tackle these two objectives concurrently (Fig. 1a). This 
synergy can only be achieved if sequencing data from explained cases (Fig. 2), unexplained 
cases and unaffected individuals are analysed jointly and if consent to contact participants for 
follow-up studies has been obtained at enrolment. We have shown that long-read sequencing 
can aid the identification of complex structural variants, which can still be called unreliably by 
short-read WGS. We have demonstrated the utility of data aggregation and sharing through the 
number of genetic associations we have found across a diversity of rare diseases (Fig. 3). This 
study follows on from large-scale whole-exome and shallow genome sequencing studies in the 
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which wasthis version posted February 18, 2020. . https://doi.org/10.1101/507244doi: bioRxiv preprint 
UK68, 69 and has been the blueprint for the UK's 100,000 Genomes Project, which recently 
completed sequencing. The NHS plans to increase provision of WGS-based diagnostics from 
8,000 to 30,000 samples per month. To achieve this aim, it has reduced the number of clinical 
genomics laboratories to seven, each servicing approximately 8 million people. It has also 
introduced a unified and consistent WGS and informatics infrastructure for these seven hubs 
and is providing training in genomics to NHS staff. We have initiated WGS of UK Biobank 
participants to study individuals with extreme values for a quantitative phenotype. Extreme trait 
values may be the result of measurement error, extreme polygenic loads47 or rare genetic 
variation and such individuals are typically excluded from GWAS studies. We have shown that 
genetic associations with the tail of a quantitative distribution can identify genes mediating 
Mendelian pathologies in the same domain of human biology (Fig. 4). The forthcoming WGS of 
0.5 million UK Biobank participants provides an opportunity to study other traits following similar 
approaches. Finally, we have provided examples of rare variants causing disease by disrupting 
non-coding REs of the genome. The reliability and affordability of WGS and the availability of 
cell-type specific epigenetic data make the exploration of the non-coding genome (Fig. 5, 
Extended Data Fig. 10) a promising focus for future research in unresolved rare disorders for 
which the aetiological cell types are known. 
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Methods 
Enrolment, research ethics and consent Patients with rare diseases and their close relatives 
were enrolled to the NIHR BioResource (NBR) as part of a pilot study for the 100,000 Genomes 
Project. For this study, 15 rare disease domains were approved after review by the Sequencing 
and Informatics Committee of the NBR. Enrolment of participants for this pilot study was 
coordinated by the University of Cambridge, started in December 2012 and was completed in 
March 2017. In addition, samples from a second rare diseases pilot study, coordinated by GEL, 
are included together with a number of control samples and samples from the UK Biobank 
cohort70. The NBR–Rare Diseases study was coordinated by the University of Cambridge. 
Participants were recruited mainly at NHS Hospitals in the UK, but also at hospitals overseas 
(Supplementary Table 1, Extended Data Fig. 1a). All 13,187 participants provided written 
informed consent, either under the East of England Cambridge South national research ethics 
committee (REC) reference 13/EE/0325 or under alternative REC-approved studies. Obtaining 
consent for overseas samples was the responsibility of the respective principal investigators at 
the hospitals where enrollment took place. The NBR retained blank versions of the consent 
forms from overseas participants and a material transfer agreement was applied to regulate the 
exchange of samples and data between the donor institutions and the University of Cambridge. 
 
Clinical and laboratory phenotype data Staff at hospitals responsible for enrolment were 
provided with the eligibility criteria for their respective domains as described above in the 
domain descriptions. The clinical and laboratory phenotype data were captured through case 
report forms (CRF) by paper questionnaires or by online CRF data capture applications and 
deposited in the NBR study database. Online data capture allowed for the free entry of HPO 
terms71 by staff at the enrolment centre and data from paper questionnaires were transformed 
into HPO terms by the study coordination office. Free text entries were transformed into HPO 
terms where feasible. An overview of the HPO data obtained for the 15 NBR rare disease 
domains is depicted in Extended Data Fig. 1c,d. 
 
DNA sequencing Samples were received as either DNA extracted from whole blood or as 
whole blood EDTA samples, which were used for extraction at the NBR laboratory in 
Cambridge. Samples were tested for adequate concentration (Picogreen), quality controlled 
(QC) for DNA degradation (gel electrophoresis) and purity (OD 260/280; Trinean) before 
selection for WGS. DNA samples were prepared at a minimum concentration of 30 ng/μl in 110 
μl, visually inspected for degradation and had to have an OD 260/280 between 1.75 and 2.04. 
They were then prepared in batches of 96 and shipped on dry ice to the sequencing provider 
(Illumina Inc, Great Chesterford, UK). Further sample QC was performed by Illumina to ensure 
that the concentration of the DNA was > 30 ng/μl and that every sample generated high quality 
genotyping results (Illumina Infinium Human Core Exome microarray). Samples with a repeated 
array genotyping call rate < 0.99, high levels of cross-contamination, mismatches with the 
declared gender that could not be resolved by further investigation, or for which consent had 
been withdrawn, were excluded from WGS (n=59). The genotyping data were also used for 
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positive sample identification and sample identity was verified before data delivery. In short 0.5 
μg of the DNA sample was fragmented using Covaris LE220 (Covaris Inc., Woburn, MA, USA) 
to obtain an average size of 450bp DNA fragments. DNA samples were processed using the 
Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., San Diego, CA, USA) on 
the Hamilton Microlab Star (Hamilton Robotics, Inc, Reno, NV, USA). The final libraries were 
checked using the Roche LightCycler 480 II (Roche Diagnostics Corporation, Indianapolis, IN, 
USA) with KAPA Library Quantification Kit (Kapa Biosystems Inc., Wilmington, MA, USA) for 
concentration. From February 2014 to June 2017 three read lengths were used: 100bp, 125bp 
and 150bp (377, 3,154 and 9,656 samples, respectively). Samples sequenced with 100bp and 
125bp reads utilised three and two lanes of an Illumina HiSeq 2500 instrument, respectively, 
while samples sequenced with 150bp reads utilised a single lane of a HiSeq X instrument. At 
least 95% of the autosomal genome had to be covered at 15X and a maximum of 5% of insert 
sizes had to be less than twice the read length. Following sample and data QC at Illumina, 
13,187 sets of WGS data files were received at the University of Cambridge High Performance 
Computing Service (HPC) for further QC. 
 
WGS data processing pipeline The WGS data for the 13,187 samples returned by the 
sequencing provider underwent a series of processing steps (Extended Data Fig. 2), described 
in detail in the Supplementary Information. Briefly, the samples were sex karyotyped and 
pairwise kinship coefficients were computed. This information was used to check for repeat 
sample submissions and sample swaps. Additionally, four further QC checks were applied to 
ensure the SNVs and indels were of a high standard. Overall, 150 samples (1.1%) were 
removed, leaving a dataset of 13,037 samples for downstream analysis. The 13,037 individuals 
were assigned one of the following ethnicities: European, African, South Asian, East Asian or 
Other. Pairwise relatedness adjusted for population stratification was then computed and used 
to generate networks of closely related individuals and to define a maximal set of 10,259 
unrelated individuals. The variants in the 13,037 individuals were left-aligned and normalised 
with bcftools, loaded into our HBase database and filtered on their overall pass rate (OPR), 
defined in the Supplementary Information. The sex karyotypes, the ethnicities and the 
relatedness estimates were used, along with enrolment information, to annotate the samples 
and variants. Samples were annotated with: affected/unaffected status, membership of the set 
of probands, membership of the maximal unrelated set, ethnicity and sex karyotype. Variants 
were annotated with CellBase consequence predictions, HGMD information where available 
and population-specific allele frequencies.  
 
Pertinent findings For each of the 15 rare disease domains (i.e. all domains except UKB, 
CNTRL and GEL) a list of DGGs was generated by domain-specific experts. Genes were 
included in the lists if there was a high enough level of evidence in the literature for gene-
disease association. The 2,497 gene/domain pairs, encompassing 2,073 unique DGGs across 
all domains, were manually curated and annotated with the relevant RefSeq and/or Ensembl 
transcript identifiers to support variant reporting. Transcripts were selected based on, by order 
of priority, community input, presence in the Locus Reference Genomic (LRG) resource72 or 
designation as canonical in Ensembl. Variants (SNVs, indels) were shortlisted if (i) their MAF in 
control populations73 was < 1/1,000 for putative novel causal variants and < 25/1,000 for 
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variants listed as disease-causing in HGMD, (ii) their predicted impact according to the Variant 
Effect Predictor74 was “HIGH” or “MODERATE” or if the consequences with respect to the 
designated transcript included one of “splice_region_variant” or 
“non_coding_transcript_exon_variant”  if the variant was in a non-coding gene, (iii) the variant 
affected a DGG relevant to the patient’s disease. Variants with more than 3 alleles or a MAF >= 
10% in the diseases cohort were discarded to, respectively, guard against errors in repetitive 
regions and remove potential systematic artefacts. The above filtering criteria were applied 
universally to all domains, except for ICP which adopted a higher MAF threshold of 3% for both 
novel and previously reported variants. The higher threshold accounted for causal variants 
being present in the male and non-child bearing female population. This strategy reduced the 
number of variants for review by the MDT from about 4 million per person to fewer than 10, 
while confidently retaining known regulatory or moderately common pathogenic variants. For 
each affected participant with prioritised variants, the variant calls, HPO-coded phenotype and 
the relevant metadata (unique study numbers; referring clinician and hospital; self-declared 
gender and genetically inferred sex, ancestry, relatedness, and consanguinity level) were 
transferred to Congenica Inc (Cambridge, United Kingdom) for visualisation in the SapientiaTM 
web application during MDT meetings. MDTs brought together experts from different hospitals 
across the UK and abroad, and typically consisted of an experienced clinician with domain-
specific knowledge, a scientist with experience in clinical genomics, a clinical bioinformatician 
and a member of the reporting team. Assignment of the level of pathogenicity followed the 
American College of Medical Genetics guidelines6 and variants (V) were marked in SapientiaTM 
as pathogenic, likely pathogenic or of uncertain significance (VUS). Only pathogenic and likely 
pathogenic variants were systematically reported and VUSs were reported at the MDT’s 
discretion. As per REC-approved study protocol, secondary findings (e.g. breast cancer 
pathogenic variants in BRCA1 in patients not presenting with this phenotype) were not reported. 
 
Genetic association testing in genes We used the BeviMed statistical method5 to identify 
genetic associations with rare diseases in our dataset. Each run of BeviMed requires the 
definition of a set of cases and controls, all of which should be unrelated with each other, and a 
set of rare variants to include in the inference. To achieve adequate power, the cases should be 
chosen such that they potentially share a common genetic aetiology (e.g. because the 
phenotypes are similar) and the rare variants should be chosen such that they potentially share 
a mechanism of action on phenotype (e.g. because they are predicted to have a similar effect 
on a particular gene product). BeviMed computes PP values of no association, dominant 
association and recessive association and, conditional on dominant or recessive association, it 
computes the PP that each variant is pathogenic. We can impose a prior correlation structure on 
the pathogenicity of the variants that reflects competing hypotheses as to which class of variant 
is responsible for disease. These classifications typically group variants by their predicted 
consequences. The class of variant responsible can then be inferred by BeviMed, thereby 
suggesting a particular mechanism of disease. The methodology is described in further detail in 
the Supplementary Information and in reference5. 
 
Regulome analysis We applied the BLUEPRINT protocol for ChIP-seq data analysis 
(http://dcc.blueprint-epigenome.eu/#/md/chip_seq_grch37). We defined regulomes for activated 
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CD4+ T cells (aCD4), B cells (B), erythroblasts (EB), megakaryocytes (MK), monocytes (MON) 
and resting CD4+ T cells (rCD4). For each cell type, we used open chromatin data (ATAC-seq 
or DNAse-seq) and histone modification data (H3K27ac) to identify REs using the RedPop 
method (see below). Additionally, for MK and EB, we had access to the following transcription 
factor (TF) ChIP-seq data, which were used to call peaks (see below) and supplement the 
regulomes: FLI1, GATA1, GATA2, MEIS1, RUNX1, TAL1 and CTCF for MK; GATA1, KLF1, 
NFE2 and TAL1 for EB; and CTCF for MON and B. For each cell type, the regulome build 
process proceeded as follows: 1. Call RedPop regions using ATAC-seq/DNAse-seq and 
H3K27ac-seq data; 2. Call TF/CTCF binding peaks using ChIP-seq data if available and obtain 
enrichment scores; 3. Discard TF regions with an enrichment score < 10 unless they overlap 
between at least two different TFs; 4. Collapse overlapping features to obtain a single genomic 
track; 5. Merge features within 100bp of each other. Each regulome feature was assigned a 
gene label using either gene annotations from Ensembl (v75) or a compendium of previously 
published promoter capture Hi-C data (pcHi-C)52 as follows: 1. Assign to a gene if the feature 
overlaps the gene or the region up to 10Kb either side of the gene body; 2. Assign to a gene if 
the feature overlaps the gene’s pcHi-C ‘blind’ spot. This region is defined by three HindIII 
restriction fragments, incorporating the capture fragment overlapping target gene TSS, and 5’ 
and 3’ adjacent fragments; 3. Assign to a gene if the feature overlaps a linked promoter 
interacting region identified using pcHi-C in the same cell type. 
 
Functional analysis of the GATA1 enhancer/HDAC6 deletion The GATA1 enhancer/HDAC6 
deletion was confirmed by PCR using primers HDAC6-F: 5’-catcttcaagaggatcagagg and 
HDAC6-R: 5’-catagctagacactggtt. Electron microscopy for platelets was performed as 
described55. Immunostaining of resting and fibrinogen spread platelets was performed as 
described44 and analyzed by Structured Illumination Microscopy (SIM, Elyra S.1, Zeiss, 
Heidelberg, D.E). Total protein lysates were obtained from platelets for immunoblot analysis as 
described75. The following antibodies were used for SIM and immunoblot analysis: rabbit anti-
HDAC6 (clone D2E5, Cell Signaling technology, Danvers, MA, USA), mouse anti-acetylated 
tubulin antibody (clone 6-11B-1, Sigma, St Louis, MO, USA), mouse anti-alpha-tubulin (A11126, 
Thermo Fisher Scientific, Waltham, MA, USA), rabbit anti-VWF (Dako, Aligent Technologies, 
Leuven, BE), mouse anti-CD63 and rat anti-GATA1 N6 (Santa Cruz Biotechnology, Dallas, TX, 
USA), rabbit anti-GATA1 (NF that was produced against recombinant N-terminal zinc finger76, 
rabbit anti-GAPDH (14C10, Cell Signaling) and anti-β3 integrin (sc-14009; Santa Cruz 
Biotechnology).  
 
MPL expression on platelets The level of MPL protein on the platelet membrane was 
measured by flow cytometry (Beckman Coulter FC500) using the monoclonal antibodies: APC-
labelled IgG1 against CD42b (clone HIP1, BD Pharmingen, number: 551061), PE-labelled IgG1 
against CD110 (clone REA250, Miltenyi Biotec) and a PE-labelled isotype control (clone MOPC-
21, BD Pharmingen, number: 555749). In short, a sample of EDTA anticoagulated blood was 
incubated with anti-CD110 (or control) and anti-CD42b for 30 minutes. Mean fluorescence 
intensity (MFI) produced by the anti-CD110 was measured by flow cytometry on cells gated on 
the CD42b APC signal, side and forward scatter. 
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Nanopore sequencing Oxford Nanopore-based sequencing of long-range PCR-amplified 
target DNA was performed as previously described77 with the aim to resolve the genetic 
architecture of intron 9 of ITGB3 in a case with Glanzmann’s thrombasthenia. The flow cell ran 
for 3 hours, and the mean coverage was 863,986X. 
 
Code availability Code to run HBASE is available from https://github.com/mh11/VILMAA. The 
RedPop software package is available from https://gitlab.haem.cam.ac.uk/et341/redpop/.  
 
Data availability Genotype and phenotype data from the 4,835 participants enrolled in the 
NIHR BioResource for the 100,000 Genomes Project–Rare Diseases Pilot can be accessed by 
seeking access via Genomics England Limited following the procedure outlined at: 
https://www.genomicsengland.co.uk/about-gecip/joining-research-community/. The genotype 
data for the 764 UK Biobank samples will be made available through a data release process 
overseen by UK Biobank (https://www.ukbiobank.ac.uk/). The phenotype data from UK Biobank 
participants are available from UK Biobank using their normal  access procedures. 
The genotype data from the vast majority of the remaining 7,438 NBR participants have been 
deposited in the European Genome-phenome Archive (EGA) at the EMBL European 
Bioinformatics Institute. Deposition of genotype at EGA is grouped by rare disease domain: 
EGA accession codes: BPD: EGAD00001004519, CSVD: EGAD00001004513, EDS: 
EGAD00001005123, HCM: EGAD00001004514, ICP: EGAD00001004515, IRD: 
EGAD00001004520, LHON: EGAD00001005122, MPMT: EGAD00001004521, NDD: 
EGAD00001004522, NPD: EGAD00001004516, PAH: EGAD00001004525, PID: 
EGAD00001004523, PMG: EGAD00001004517, SMD: EGAD00001004524, SRNS: 
EGAD00001004518. Access to genotype data provided by the EGA is overseen by a Data 
Access Committee (DAC) (https://www.ebi.ac.uk/ega/). Access to all NBR WGS data and 
detailed phenotype data on the 7,438 NBR participants can be requested by completing the 
NBR Data Access Agreement application (dac@bioresource.nihr.ac.uk). 
 
The ATAC-seq and H3K27ac ChIP-seq data to support the generation of the regulomes are 
available from GEO or EGA, or referenced to their publication as follows. H3K27ac ChIP-seq: 
aCD478, B (ERR1043004, ERR1043129, ERR928206, ERR769436), EB (EGAD00001002377), 
MK (EGAD00001002362), MON (ERR829362 (ERS257420), ERR829412 (ERS222466), 
ERR493634 (ERS214696)), rCD478. ATAC-seq: aCD4 (GSE124867), B (SRR2126769 
(GSE71338)), EB (SRR5489430 (GSM2594182)), MK (EGAD00001001871), MON (accession 
number requested), rCD4 (GEO accession will be available before publication).  
 
MDT-reported alleles and their clinical interpretation have been deposited in ClinVar (under the 
name “NIHR Bioresource Rare Diseases”) and DECIPHER. 
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